AmacaThera
AmacaThera is a clinical-stage biotechnology company dedicated to transforming therapeutics through innovative drug delivery platforms. Their unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas, including post-surgical pain management, cancer, and hard-to-reach targets. The company aims to revolutionize treatment options using advanced hydrogel formulations, with a focus on reducing opioid dependency and addressing unmet medical needs.
Industries
Nr. of Employees
small (1-50)
AmacaThera
MaRS Centre, West Tower, 661 University Ave Suite 1300, Toronto, ON M5G 0B7
Products
AMT‑143 (lead sustained‑release local anesthetic)
A slow‑release, non‑opioid local anesthetic formulation designed for single‑administration, localized post‑operative pain control delivered via an injectable hydrogel depot.
Injectable thermoresponsive hydrogel platform
A fast‑gelling thermoresponsive hydrogel platform designed to liquefy under shear for syringe delivery and gel at body temperature to form a local depot compatible with small molecules, biologics, lipid nanoparticles and cells.
AMT‑143 (lead sustained‑release local anesthetic)
A slow‑release, non‑opioid local anesthetic formulation designed for single‑administration, localized post‑operative pain control delivered via an injectable hydrogel depot.
Injectable thermoresponsive hydrogel platform
A fast‑gelling thermoresponsive hydrogel platform designed to liquefy under shear for syringe delivery and gel at body temperature to form a local depot compatible with small molecules, biologics, lipid nanoparticles and cells.
Services
Partnered evaluation and option agreements to co‑develop long‑acting injectable formulations for new markets, including veterinary and human health applications.
Formulation development and preclinical testing services focusing on sustained‑release local delivery, release kinetics, and payload compatibility.
Clinical program management for first‑in‑human and early efficacy studies including safety, tolerability, pharmacokinetics and clinical activity endpoints for local depot formulations.
Partnered evaluation and option agreements to co‑develop long‑acting injectable formulations for new markets, including veterinary and human health applications.
Formulation development and preclinical testing services focusing on sustained‑release local delivery, release kinetics, and payload compatibility.
Clinical program management for first‑in‑human and early efficacy studies including safety, tolerability, pharmacokinetics and clinical activity endpoints for local depot formulations.
Expertise Areas
- Localized sustained‑release drug delivery
- Hydrogel biomaterials for therapeutic delivery
- Clinical trial management (Phase I and early Phase II)
- Sterile injectable manufacturing and scale‑up
Key Technologies
- Thermoresponsive, shear‑thinning hydrogel materials
- Injectable depot formation at body temperature
- Controlled‑release formulation technologies
- Pharmacokinetic and release‑kinetics assays
News & Updates
June 13th, 2024 Media Coverage. RBCx, the tech banking and investment arm of the Royal Bank of Canada, has featured AmacaThera’s drug development platform and start-up journey.
May 15th, 2024 Press Release. AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management.
November 28th, 2023 Press Release. AmacaThera announced the closing of a CAD$4.0 million financing round to support the development of its lead product, AMT-143, aimed at providing long-acting, non-opioid post-surgical pain relief.
September 27th, 2021 Press Release. AmacaThera was recognized as one of Canada's most innovative early-stage technology companies at the CIX Digital Summit.
November 29th, 2020 Media Coverage. Professor Molly Shoichet, co-founder of AmacaThera, received the prestigious Gerzhard Herzberg Canada Gold Medal for her outstanding contributions to regenerative medicine and hydrogel research.
June 13th, 2024 Media Coverage. RBCx, the tech banking and investment arm of the Royal Bank of Canada, has featured AmacaThera’s drug development platform and start-up journey.
May 15th, 2024 Press Release. AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management.
November 28th, 2023 Press Release. AmacaThera announced the closing of a CAD$4.0 million financing round to support the development of its lead product, AMT-143, aimed at providing long-acting, non-opioid post-surgical pain relief.
September 27th, 2021 Press Release. AmacaThera was recognized as one of Canada's most innovative early-stage technology companies at the CIX Digital Summit.
November 29th, 2020 Media Coverage. Professor Molly Shoichet, co-founder of AmacaThera, received the prestigious Gerzhard Herzberg Canada Gold Medal for her outstanding contributions to regenerative medicine and hydrogel research.